Natus Medical INC: directors' dealings · United States · SEC (Form 4)

About Natus Medical INC

NATUS MEDICAL INC. (ticker NTUS) is a U.S.-listed medical technology company trading on the NYSE/NASDAQ market in the United States. The group focuses on screening, diagnosing, and treating disorders affecting the brain and neural pathways, while its Sensory platform extends the portfolio into hearing and balance assessment, vision screening, and newborn care. In investor terms, Natus is a specialized healthcare equipment and workflow company rather than a broad-based medtech conglomerate: its value proposition is built on clinical depth, integrated hardware, software, consumables, services, and training. Founded in 1987, Natus presents itself as a technology pioneer with a long operating heritage and more than 80 years of brand history across its product lines. The company is headquartered in Wisconsin, United States, and emphasizes a meaningful U.S. manufacturing footprint for key neurodiagnostic products. Historically, Natus has been recognized as a global leader in neurodiagnostics, with solutions deployed in hospitals, university medical centers, sleep labs, private practices, clinics, and research settings around the world. Its business is typically organized around two major pillars. The Neuro business covers EEG, EMG, polysomnography, diagnostic accessories, and monitoring systems used to acquire and interpret physiological signals. This portfolio is supported by advanced software, algorithms, service programs, field support, and clinical education. The Sensory business addresses newborn hearing screening, balance testing, vision screening, and neonatal care workflows. Together, these businesses position Natus as a provider of end-to-end clinical solutions that help clinicians detect, monitor, and respond to patient conditions more efficiently. From a competitive standpoint, Natus benefits from specialized know-how, a large installed base, and recurring demand tied to hospital workflows and consumables. The company states that it sells in more than 100 countries, giving it broad geographic reach and diversified exposure beyond the U.S. market. Its market position is strongest in neurodiagnostics, where it is known for combining equipment, software, and user education into a single clinical ecosystem. That integrated approach can be a meaningful moat in settings where reliability, workflow compatibility, and clinician confidence matter as much as raw hardware specifications. Recent developments have reinforced the strategic focus on innovation. In 2025, Natus launched BrainWatch, a point-of-care EEG solution designed to support real-time seizure detection in emergency and intensive care settings. The product has also been involved in U.S. International Trade Commission proceedings, underlining its commercial importance. More recently, Natus has pursued targeted acquisitions to broaden its technology stack: Holberg EEG added AI-driven EEG interpretation capabilities, while Keriton and TheraB Medical strengthened the Sensory/newborn-care side with connected feeding management and wearable phototherapy solutions. For French-speaking investors, Natus stands out as a focused healthcare technology platform with exposure to structurally attractive niches such as neurology, neonatal care, and hospital digitalization.